ArticleNature communications2022
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02719977 (A Phase I Study of CX5461), which is not on this map. Cited by 84 papers.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Study of CX5461
Who cites it
84 citing papers in PubMed, 132 citations in OpenAlex.
- Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia.Leukemia · 2026Article
- The UVA-induced single-base mutational signature of CX-5461 in human cells.Nucleic acids research · 2026Article
- G-quadruplex DNA reprograms the photochemistry of CX-5461 toward radical-driven anticancer activity.Nucleic acids research · 2026Article
- G-quadruplex structures as regulators of cellular processes and drivers of genome instability in cancer.Critical reviews in biochemistry and molecular biology · 2026Review
- In vivo CRISPR knockout screen identifies Polr1a as a key driver and a potential therapeutic target for melanoma metastasis.Oncogene · 2026Article
- The Nucleolus in Human Disease: Ribosome Biogenesis, Nucleolar Surveillance, and Therapeutic Opportunities.Biomolecules · 2026Review
- Detangling knots: the intricate roles of G-quadruplexes in herpesvirus replication.Journal of virology · 2026Review
- RLASON-CDR: a reinforcement learning-driven adaptive synergistic optimization network for cancer drug response prediction.Briefings in bioinformatics · 2026Article
- Structural insights into the binding of CX-5461 and MTR-106 to G-quadruplex DNA.Nucleic acids research · 2026Article
- Multi-omics dissection of R-loop dynamics in tumorigenesis: From transcription-replication conflict to therapeutic targets.Molecular therapy. Oncology · 2026Review
- G quadruplex DNA facilitates a pervasive path to homologous recombination.bioRxiv : the preprint server for biology · 2026Article
- The SMARCA4 subunit of the SWI/SNF complex prevents genome instability at G quadruplexes.Genome biology · 2026Article
- Rare genetic diseases associated with G-quadruplex-induced replication stress.Communications biology · 2026Review
- DNA damaging properties of G-quadruplex ligand QN-302 are potentiated by the DNA repair inhibitor Olaparib and mitigated by the molecular helicase PhpC.Genome biology · 2026Article
- G-quadruplex stabilization via small molecules as a potential anti-cancer strategy.Cellular & molecular biology letters · 2026Review
- Article
- CX-5461 and doxorubicin activate a shared DNA damage-associated transcriptional response in human cardiomyocytes.G3 (Bethesda, Md.) · 2026Article
- Ubiquitination of Oncogenic Mutant p53 via Attenuation of Ribosome Biogenesis Machinery Effectively Inhibits Pancreatic Tumor Growth.Molecular cancer therapeutics · 2026Article
- Fibrillarin: bridging ribosome biogenesis and apoptosis in cellular stress and disease.Apoptosis : an international journal on programmed cell death · 2026Review
- Natural G-Quadruplex Stabilizers: A Targeted Strategy for Breast Cancer Therapy.Drug design, development and therapy · 2026Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 7 institutions in 1 country.
John Hilton *Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Karen Gelmon *BC Cancer - Vancouver Centre, Vancouver, BC, V5Z 1L3, Canada.
Philippe L BedardPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-6771-2999
Dongsheng TuCanadian Cancer Trials Group, 10 Stuart Street, Kingston, ON, K7L 3N6, Canada.
Hong XuMolecular Oncology, BC Cancer Research Institute, Vancouver, BC, V5Z 1L3, Canada.
Anna V TinkerBC Cancer - Vancouver Centre, Vancouver, BC, V5Z 1L3, Canada.
Rachel GoodwinOttawa Hospital Research Institute, Ottawa, ON, Canada.
Scott A LaurieOttawa Hospital Research Institute, Ottawa, ON, Canada.
Derek JonkerOttawa Hospital Research Institute, Ottawa, ON, Canada.
Aaron R HansenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Zachary W VeitchPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Daniel J RenoufBC Cancer - Vancouver Centre, Vancouver, BC, V5Z 1L3, Canada.
Linda HagermanCanadian Cancer Trials Group, 10 Stuart Street, Kingston, ON, K7L 3N6, Canada.
Hongbo LuiCanadian Cancer Trials Group, 10 Stuart Street, Kingston, ON, K7L 3N6, Canada.
Bingshu ChenCanadian Cancer Trials Group, 10 Stuart Street, Kingston, ON, K7L 3N6, Canada.ORCID 0000-0001-6139-0696
Deb KellarOttawa Hospital Research Institute, Ottawa, ON, Canada.
Irene LiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Sung-Eun LeeBC Cancer - Vancouver Centre, Vancouver, BC, V5Z 1L3, Canada.
Takako KonoMolecular Oncology, BC Cancer Research Institute, Vancouver, BC, V5Z 1L3, Canada.
Brian Y C ChengMolecular Oncology, BC Cancer Research Institute, Vancouver, BC, V5Z 1L3, Canada.ORCID 0000-0002-9258-8184
Damian YapMolecular Oncology, BC Cancer Research Institute, Vancouver, BC, V5Z 1L3, Canada.ORCID 0000-0002-5370-4592
Daniel LaiMolecular Oncology, BC Cancer Research Institute, Vancouver, BC, V5Z 1L3, Canada.ORCID 0000-0001-9203-6323
Sean BeattyMolecular Oncology, BC Cancer Research Institute, Vancouver, BC, V5Z 1L3, Canada.ORCID 0000-0001-6819-7071
John SoongSenhwa Biosciences, Inc, Taipei, Taiwan.
Kathleen I PritchardSunnybrook Health Sciences Centre, Toronto, ON, Canada.
Isabel Soria-BretonesPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Eric ChenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Harriet FeilotterCanadian Cancer Trials Group, 10 Stuart Street, Kingston, ON, K7L 3N6, Canada.
Moira RushtonCanadian Cancer Trials Group, 10 Stuart Street, Kingston, ON, K7L 3N6, Canada.
Lesley SeymourCanadian Cancer Trials Group, 10 Stuart Street, Kingston, ON, K7L 3N6, Canada. lseymour@ctg.queensu.ca.ORCID 0000-0001-8081-0799
Samuel AparicioMolecular Oncology, BC Cancer Research Institute, Vancouver, BC, V5Z 1L3, Canada.ORCID 0000-0002-0487-9599
David W CesconPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-1080-0998
University Health Network · CACanadian Partnership Against Cancer · CATerry Fox Research Institute · CAOttawa Hospital · CACanadian Cancer Society · CASunnybrook Health Science Centre · CAUniversity of British Columbia Hospital · CA
Funding
CIHR FDN-148429
Abstract
CX-5461 is a G-quadruplex stabilizer that exhibits synthetic lethality in homologous recombination-deficient models. In this multicentre phase I trial in patients with solid tumors, 40 patients are treated across 10 dose levels (50-650 mg/m
Indexed as
NeoplasmsBenzothiazolesDNAHumansNaphthyridinesBenzothiazolesCX 5461DNANaphthyridines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT02719977ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.